About Longeveron Inc. Common Stock
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Market Cap
$0.03B
Employees
25
Listed Since
February 12, 2021
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.longeveron.comPhone
305-302-7158
Headquarters
1951 NW 7TH AVENUE
MIAMI, FL 33136
CIK
0001721484